aTyr Pharma Inc. Announces New Phase‑3 Trial for Pulmonary Sarcoidosis Drug
San Diego, California – On 12 May 2026, aTyr Pharma Inc. (NASDAQ: ATYR) disclosed that its flagship product, efzofitimod, will enter a new Phase‑3 clinical trial for the treatment of pulmonary sarcoidosis. The announcement was made following a recent FDA Type C meeting, in which the company provided regulatory and clinical updates on efzofitimod.
Regulatory and Clinical Update
On 11 May 2026, aTyr Pharma issued a regulatory and clinical update to the U.S. Food and Drug Administration. The update detailed progress on efzofitimod, a protein therapeutic under development for pulmonary sarcoidosis. The update was part of a Type C meeting, a procedural step that allows the FDA to discuss data and clinical plans with the sponsor.
New Phase‑3 Trial
The new Phase‑3 study expands the investigation of efzofitimod into pulmonary sarcoidosis. According to a separate announcement on the same day, the company outlined the trial’s design, objectives, and anticipated timelines. This development follows earlier Phase‑2 data that suggested clinical benefit in patients with this condition.
Market Reaction
Shares of aTyr Pharma fell on 12 May 2026 after the announcement, reflecting investor concerns about the timing and scope of the new trial. The decline followed a brief uptick during the day’s trading session. The company’s stock closed at USD 0.9502 on 10 May 2026, with a 52‑week high of USD 7.29 and a 52‑week low of USD 0.64. The market capitalization stands at approximately USD 92 million, and the price‑to‑earnings ratio is negative at –1.165.
Company Overview
aTyr Pharma is a biotechnology firm headquartered in San Diego, California, that focuses on discovering and developing therapeutics based on physiocrines. The company operates within the health‑care sector and serves customers nationwide in the United States. Further information can be found on its website, www.atyrpharma.com , or through Nasdaq trading.
